Joshua K. Sabari, MD

Articles

Dr Sabari on the FDA Approval of Amivantamab/Lazertinib in EGFR+ Advanced NSCLC

September 4th 2024

Joshua K. Sabari, MD, discusses FDA approval of first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

August 8th 2024

The panel discusses treatment considerations for consolidation durvalumab.

Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

August 8th 2024

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease

August 8th 2024

The panel looks at a second patient case study.

Management of Resectable Early Stage NSCLC with Actionable Mutations

August 8th 2024

The panel discusses management of resectable early-stage non–small cell lung cancer.

Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

August 8th 2024

The panel discusses the factors that go into selecting patients for adjuvant therapy.

Management of Borderline Resectable NSCLC

August 8th 2024

The panel discusses reassessing for respectability after certain treatments.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

July 25th 2024

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC

July 12th 2024

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

July 12th 2024

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.

Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

June 25th 2024

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

June 25th 2024

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

March 29th 2024

Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.

Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study

February 26th 2024

Joshua K. Sabari, MD, reviews data from the 5-year overall survival update from the POSEIDON study investigating durvalumab, tremelimumab, and chemotherapy in first-line metastatic non–small cell lung cancer.

Dr Sabari on the Potential Role for Patritumab Deruxtecan in NSCLC

February 9th 2024

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

Clinical Pearls and Future Perspectives in Advanced NSCLC

January 3rd 2024

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

Future Perspectives in KRAS G12C-Mutated NSCLC

December 28th 2023

In closing, experts share future perspectives in KRAS G12C-mutated NSCLC, emphasizing novel targeted therapies and emerging trials in the evolving treatment landscape.

Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

December 28th 2023

Shared insight on the clinical management of hepatotoxicity with use of KRAS G12C inhibitors in mNSCLC.

Antibody-Drug Conjugates in EGFR-Mutant NSCLC

December 27th 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

December 27th 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.